Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures

BACKGROUND AND AIM: Cardiovascular diseases (CVDs) are globally the leading cause of death and hypertension is a significant risk factor. Treatment with glucagon-like peptide-1 (GLP-1) receptor agonists has been associated with decreases in blood pressure and CVD risk. Our aim was to investigate the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cardiovasc Diabetol
Main Authors: Lundgren, Julie R., Færch, Kristine, Witte, Daniel R., Jonsson, Anna E., Pedersen, Oluf, Hansen, Torben, Lauritzen, Torsten, Holst, Jens J., Vistisen, Dorte, Jørgensen, Marit E., Torekov, Signe S., Johansen, Nanna B.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6778378/
https://ncbi.nlm.nih.gov/pubmed/31586493
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-019-0937-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados